C

Can-Fite BioPharma Ltd
D

CANF

1.78000
USD
-0.06
(-3.26%)
مغلق
حجم التداول
7,926
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
10,851,642
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AEMD
    -0.01550
    (-2.58%)
    0.58640 USD
    A
    APDN
    -0.00530
    (-3.25%)
    0.15790 USD
    A
    AXON
    -28.72
    (-5.30%)
    513.31 USD
    M
    MESA
    -0.06500
    (-5.31%)
    1.16000 USD
    O
    OCUL
    -0.26000
    (-3.58%)
    6.99500 USD
    المزيد
الأخبار
المقالات

العنوان: Can/Fite BioPharma Ltd

القطاع: Healthcare
الصناعة: Biotechnology
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed intoa Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).